Gwyneth Paltrow has a new Netflix show coming up in a couple of weeks called “The Goop Lab” and her Goop company promotes a lot of wacky things so one Sunday over lunch I thought I’d take a look at what they sell related to stem cells. Going into this, I didn’t know for sure […]
As Goop Lab TV show approaches, my look at their ‘stem cell’ products Read More »
Every year in December and early January I do a post predicting some key events for the stem cell and regenerative medicine field for the upcoming year and today’s post contains my predictions for 2020. You can see my past 2019 predictions along with my grades for them here. I gave myself a B+ for
20/20 vision? The Niche’s 20 stem cell & regenerative medicine predictions for 2020 Read More »
Last year around this time I took my annual plunge to make 20 predictions for the coming year for the stem cell and regenerative medicine field. I even made a crystal ball graphic to highlight the complexity of the stem cell ecosystem into which these predictions were embedded (see image) for 2019. How’d I do?
B+ on my report card on my 20 stem cell predictions for 2019 Read More »
The NIH announced the launch of the 1st autologous induced pluripotent stem (IPS) cell trial for vision loss in the U.S., focused on macular degeneration. The protocol is based on a solid foundation of pre-clinical animal studies: “Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a
1st autologous IPS cell clinical trial for vision loss in the US Read More »
A variety of states have stepped up to address unproven stem cell clinics within their borders and the latest is Vermont. According to the VTDigger and writer Anne Wallace Allen, the Vermont Medical Society is planning a number of steps to address this situation. For example, at their encouragement a Vermont lawmaker will introduce legislation
Vermont zeroes in on unproven stem cell clinics Read More »
By Jeanne Loring 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 blast off! It’s good to get out of the lab occasionally to get a different perspective. Last Thursday, December 5, I got a very different perspective, in Cape Canaveral, Florida, where I got to watch the SpaceX Dragon spacecraft be launched by
Stem cells blast into space: Jeanne Loring on the big launch & project specs Read More »
Here in the U.S. we just had our big Thanksgiving holiday, but science goes, stem cells keep growing and needing attention, and it’s another weekend chance to catch up on our paper reading. Here’s this weekend edition of recommended reads including news items and pubs. From Cell Stem Cell: Single-Cell Transcriptome Analysis of Uniparental Embryos Reveals
The FDA just sent another untitled letter to a producer of a potentially non-compliant perinatal “stem cell” product that may be an unapproved drug. This follows past non-warning letters and/or inspection reports made public to Liveyon, R3 Stem Cell, Stemell, and others. RAPS has more on the story of the new letter here. This newest
Another FDA letter to a stem cell clinic supplier: what’s the agency’s long game? Read More »
Once upon a time this blog and major outlets around the world were regularly writing about a Japanese stem cell researcher named Haruko Obokata (小保方 晴子). Whatever happened to Obokata and the other folks directly involved in STAP cell research? First, a bit of background because maybe still a few people never heard of STAP cells
Whatever happened to the STAP cell scientists including Haruko Obokata? Read More »
By Guillaume Levrier Human germline editing has been done before. It will be done again in the future, as it is relatively easy to perform. No mechanism with the de facto ability to prevent it from being organized has yet been designed, let alone implemented. But the fact that germline editing has, can, and will